Inhibikase Therapeutics Ownership | Who Owns Inhibikase Therapeutics?

Inhibikase Therapeutics Ownership Summary

Inhibikase Therapeutics is owned by 5.20% institutional investors, 12.99% insiders, and 81.81% retail investors. Sands capital ventures is the largest institutional shareholder, holding 12.17% of IKT shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 2.83% of its assets in Inhibikase Therapeutics shares.

IKT Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Inhibikase Therapeutics	5.20%	12.99%	81.81%
Sector	Healthcare Stocks	232.01%	10.74%	-142.75%
Industry	Biotech Stocks	381.47%	10.55%	-292.02%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Sands capital ventures	10.95M	12.17%	$17.74M
Soleus capital management	10.88M	12.08%	$22.29M
Fairmount funds management	6.13M	6.80%	$9.92M
Perceptive advisors	5.42M	6.02%	$8.78M
Commodore capital lp	5.40M	6.00%	$8.74M
Adar1 capital management	5.25M	5.83%	$8.50M
Vanguard group	4.56M	5.06%	$9.35M
Nantahala capital management	3.93M	4.36%	$8.06M
Blackrock funding, inc. /de	3.31M	3.67%	$6.78M
Blackstone	2.64M	2.93%	$4.27M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Sands capital ventures	10.95M	3.89%	$17.74M
Caxton	28.45K	1.36%	$58.33K
Stonepine capital management	735.02K	0.97%	$1.19M
Fairmount funds management	6.13M	0.89%	$9.92M
Soleus capital management	10.88M	0.82%	$22.29M
Adar1 capital management	5.25M	0.80%	$8.50M
Commodore capital lp	5.40M	0.43%	$8.74M
Nantahala capital management	3.93M	0.27%	$8.06M
Perceptive advisors	5.42M	0.25%	$8.78M
Blackstone	2.64M	0.02%	$4.27M

Top Buyers

Holder	Shares	% Assets	Change
Soleus capital management	10.88M	0.82%	4.55M
Nantahala capital management	3.93M	0.27%	1.74M
Vanguard group	4.56M	0.00%	1.29M
Blackrock funding, inc. /de	3.31M	0.00%	230.39K
Adar1 capital management	5.25M	0.80%	125.50K

Top Sellers

Holder	Shares	% Assets	Change
Marshall wace, llp	-	-	-155.27K
Balyasny asset management	-	-	-81.16K
Omers administration	-	-	-56.00K
Ubs group	94.55K	-	-41.73K
Fmr	105.77K	-	-38.47K

New Positions

Holder	Shares	% Assets	Change	Value
Jane street group	116.00K	-	116.00K	$237.81K
Virtu financial	13.45K	0.00%	13.45K	$22.00K
Sanctuary advisors	12.54K	0.00%	12.54K	$25.70K
Hrt financial lp	10.57K	0.00%	10.57K	$21.00K
Russell investments group	7.70K	-	7.70K	$12.48K

Sold Out

Holder	Change
Srs capital advisors	-86.00
Raymond james financial	-1.00K
Point72 (difc)	-1.98K
Cubist systematic strategies	-9.04K
Brevan howard capital management lp	-10.38K

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Dec 31, 2025	7	-86.79%	4,678,736	-91.49%	5	0.14%	5	-78.26%	2	-86.67%
Sep 30, 2025	12	-75.00%	3,752,410	-93.12%	4	0.11%	4	-88.57%	5	-16.67%
Jun 30, 2025	48	6.67%	54,512,380	20.28%	60	2.38%	37	19.35%	6	100.00%
Mar 31, 2025	47	51.61%	51,462,756	2.80%	57	0.13%	31	3.33%	3	-
Dec 31, 2024	31	181.82%	50,059,308	5719.28%	211	1604.08%	30	500.00%	-	-100.00%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Vanguard Total Stock Mkt Idx Inv	3.43M	2.83%	-
iShares Russell 2000 ETF	1.27M	1.04%	1.27M
Fidelity Small Cap Index	602.10K	0.50%	-716.00
iShares Russell 2000 Value ETF	462.40K	0.38%	462.40K
Vanguard Institutional Extnd Mkt Idx Tr	371.56K	0.31%	-
Vanguard Russell 2000 ETF	288.60K	0.24%	-9.24K
Fidelity Select Biotechnology	141.97K	0.19%	-2.20K
State St Russell Sm Cap® Indx SL Cl I	210.40K	0.17%	-
Fidelity Extended Market Index	192.13K	0.16%	12.35K
iShares Micro-Cap ETF	158.29K	0.13%	158.29K

Recent Insider Transactions

Date	Name	Role	Activity	Value
Nov 21, 2025	Sands Capital Life Sciences Pulse Fund II, L.P.	-	Buy	$3.00M
Oct 21, 2024	Bellini Roberto	-	Buy	$2.00M
Oct 21, 2024	Kush Arvind	-	Buy	$198.65K
Oct 21, 2024	Munshi Amit	-	Buy	$500.05K
Aug 16, 2022	Werner Milton H.	President and CEO	Buy	$4.00K

Insider Transactions Trends

Date	Buy	Sell
2026 Q1	-	-
2025 Q4	1	-
2025 Q2	-	-
2025 Q1	-	-
2024 Q4	3	-

IKT Ownership FAQ

Who Owns Inhibikase Therapeutics?

Inhibikase Therapeutics shareholders are primarily institutional investors at 5.20%, followed by 12.99% insiders and 81.81% retail investors. The average institutional ownership in Inhibikase Therapeutics's industry, Biotech Stocks , is 381.47%, which Inhibikase Therapeutics falls below.

Who owns the most shares of Inhibikase Therapeutics?

Inhibikase Therapeutics’s largest shareholders are Sands capital ventures (10.95M shares, 12.17%), Soleus capital management (10.88M shares, 12.08%), and Fairmount funds management (6.12M shares, 6.80%). Together, they hold 31.05% of Inhibikase Therapeutics’s total shares outstanding.

Does Blackrock own Inhibikase Therapeutics?

BlackRock is not among the top 10 institutional shareholders of Inhibikase Therapeutics.

Who is Inhibikase Therapeutics’s biggest shareholder by percentage of total assets invested?

Sands capital ventures is Inhibikase Therapeutics’s biggest shareholder by percentage of total assets invested, with 3.89% of its assets in 10.95M Inhibikase Therapeutics shares, valued at 17.74M$.

Who is the top mutual fund holder of Inhibikase Therapeutics shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of Inhibikase Therapeutics shares, with 2.83% of its total shares outstanding invested in 3.43M Inhibikase Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools